Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Farhat Nasim

Articles By : Farhat Nasim

Indian pharma firms lag behind global peers in RnD, Patents, Publications, reveals report

MD Bureau21 Oct 2024 2:15 PM IST

The largest disparity was observed in the number of publications per billion USD revenue, with global firms producing 8.4 times more publications than...

Allergan's Botox Cosmetic now approved for treating platysma bands

MD Bureau21 Oct 2024 2:00 PM IST

Botox Cosmetic is the first and only product with four aesthetic indication areas: forehead lines, frown lines, crow's feet lines, and now platysma...

Sanofi Rilzabrutinib earns orphan designation in EU for IgG4 related disease

Sanofi closes deal for consumer health unit Opella: Report

MD Bureau21 Oct 2024 1:18 PM IST

The breakthrough came after the investment group provided France with guarantees on maintaining jobs and production in the country

Drug Report Submissions by Marketing Firms: DTAB directs to constitute sub-committee to amend NDCT Rules

Farhat Nasim20 Oct 2024 1:00 PM IST

New Delhi: The Drugs Technical Advisory Board (DTAB) has recommended forming a sub-committee to look into the proposed amendments to the New Drugs and...

Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis treatment

Gilead withdraws bladder cancer drug Trodelvy in US

Farhat Nasim20 Oct 2024 11:00 AM IST

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients with a type of bladder...

Merck eyes more acquisitions for life science after USD 600M Mirus Bio deal

MD Bureau20 Oct 2024 10:15 AM IST

Merck also said it will intensify the in licensing of drug candidates in its Healthcare division.

CVS Health CEO steps down amid financial challenges

MD Bureau20 Oct 2024 9:45 AM IST

CVS cut its financial expectations for the third time in August with all major pharmacy chains attempting to navigate a drastically changed landscape

Kezar to terminate mid-stage trial for Lupus treatment

MD Bureau20 Oct 2024 9:30 AM IST

The regulator's decision came after the company paused the study in September to review safety data following the deaths of four patients.

AiMeD Flags Risks in GST Overhaul For Medical Devices, Seeks Balanced 5%-12% Tax Structure

DCGI to bring non-invasive medical devices like thermometers, stethoscopes under quality control

Farhat Nasim19 Oct 2024 4:39 PM IST

New Delhi: The Drugs Technical Advisory Board (DTAB) has approved a proposal to amend Rules 19H and 19J of Chapter IIIB of the Medical Devices Rules,...

Torrent Pharma: USFDA concludes inspection at Vizag facility with zero observations

NPPA slaps over Rs 6L demand notice to Torrent Pharma

MD Bureau19 Oct 2024 3:32 PM IST

The demand notice is for the launch of a new drug wherein price approval was taken after the launch, Torrent Pharma said in a regulatory filing.

Gland Pharma names Shyamakant Giri as new CEO

MD Bureau19 Oct 2024 3:29 PM IST

New Delhi: Gland Pharma has announced a major leadership change with the appointment of Shyamakant Giri as the new Chief Executive Officer (CEO),...

Merck's RSV antibody Clesrovimab for infants shows 60.4% effectiveness in mid-to-late stage clinical trial

MD Bureau19 Oct 2024 12:15 PM IST

The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok